Maria Cirino-Marcano, MD
Pulmonary Disease · Roanoke, VANPI 1730281726
Payments from drug & device makers
Across 26 payments — averaging $309.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Steris Corporation$2K
- Pulmonx Corporation$2K
- AstraZeneca$142
- Genentech USA, Inc.$141
- Olympus America Inc.$124
- plus $119 from 4 others
What the payments were for
- Grants$320%
- Travel & lodging$4,34554%
- Food & beverage$1,12814%
- Education$2,54532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $2,641 |
| Steris Corporation | 6 | $2,474 |
| Pulmonx Corporation | 9 | $2,410 |
| AstraZeneca | 3 | $142 |
| Genentech USA, Inc. | 1 | $141 |
| Olympus America Inc. | 1 | $124 |
| Pleural Dynamics Inc. | 1 | $49 |
| Cook Incorporated | 1 | $32 |
| Bayer | 1 | $19 |
| Covidien LP | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,641
- TRUFREEZE$2,342
- ZEPHYR ENDOBRONCHIAL VALVE$1,282
- Pulmonx Endobronchial Valve EBV$961
- Always-On Tip Tracked Forceps, 1.8mm OD, Serrated Cup$124
- SPiN Perc Localization Needle 19ga x 105mm, 1cm marking zone$124
- CHARTIS CATHETER$112
- ZEPHYR DELIVERY CATHETER$112
- PULMONX CHARTIS TABLET CONSOLE$112
How this compares
$8,051 in reported general payments places this provider in the 65th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 274 | $202,106 |
| Dupixent PenDupilumab | 51 | $189,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $120,850 |
| Spiriva RespimatTiotropium Bromide | 115 | $81,099 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 129 | $67,784 |
| Dupixent SyringeDupilumab | 13 | $57,382 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $24,201 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $12,607 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,203 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $10,832 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $8,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 281 | $7,489 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,610 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $6,027 |
| Fluticasone Propionate HfaFluticasone Propionate | 22 | $5,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $142 | $225,545341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Roanoke
- Moises CossioRoanoke$147K
- Frank BiscardiRoanoke$53K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.